Screener
Myriad Genetics MYGN CapEx
Discontinued — last reported Q2 '23
CapEx at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The source filing: Myriad Genetics’s 10-Q, filed August 4, 2023.
- Filed
- Aug 4, 2023
- Fiscal quarter
- Q2 FY2023
- Calendar quarter
- Q2 2023
- Accession
- 0000899923-23-000058
| Line item | Six months ended June 30, 2023 | Six months ended June 30, 2022 |
|---|---|---|
| Deferred revenues | 0.1 | (4.9) |
| Net cash used in operating activities | (34.1) | (96.2) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures | (42.3) | (13.0) |
| Purchases of marketable investment securities | — | (85.5) |
| Proceeds from maturities and sales of marketable investment securities | 88.7 | 45.2 |
| Net cash provided by (used in) investing activities | 46.4 | (53.3) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |
Item 1. Financial Statements
FAQ
- What is Myriad Genetics's capex?
- Myriad Genetics (MYGN) reported capex of $18.8M in Q2 2023.
- How has Myriad Genetics's capex changed year-over-year?
- Myriad Genetics's capex increased by 180.6% year-over-year, from $6.7M to $18.8M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Myriad Genetics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude